HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement Industry Critics On Agenda For FDA's Ingredient List Meeting

This article was originally published in The Rose Sheet

Executive Summary

FDAs Oct. 3 meeting agenda includes Pieter Cohen, Harvard Medical School professor; Consumers Union Programs Director Chuck Bell; Laura MacCleery, Center for Science in the Public Interest regulatory affairs director; and Stephanie Scarmo, Pew Charitable Trusts Health Care Products Project officer.

You may also be interested in...

FDA Expects Safety As Ticket To Enter 'Pre-DSHEA' Dietary Ingredient List

FDA agrees with public health advocates that ingredients should be on a potential list of those available when Congress passed DSHEA only after current substantiation for a reasonable expectation of safety for their intended uses.

Road To 'New' From FDA 'Old' Dietary Ingredient Discussion Has Doubters

CFSAN hosts a discussion at its College Park, Md., headquarters on developing a list of dietary ingredients available in the US food supply before Congress passed DSHEA. Food and drug law attorneys Todd Harrison and Wes Siegner make arguments that FDA is heading in the wrong direction to keep violative ingredients off the market.

CBD Or Not To Be? ODI, NDI Or IND?

Cannabidiol is found in the hemp plant and other sources and is not an intoxicant, but a "human neurotransmitter and a normal part of the cannabidiol neurotransmitter system in the human body," says "Vitamin Lawyer" Ralph Fucetola.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts